書籍詳細

I 感染症の基礎知識

P.27 掲載の参考文献

• 1) 加藤延夫 (編):医系微生物学 (第2版). 朝倉書店, 1996

• 2) Elliot, T., Hastings, M., Desselberger, U.:Lecture notes on medical microbiology. (3rd ed.) Blackwell Science, 1998

• 3) Reese, R.E., Betts, R. F.:A practical approach to infectious diseases. (4th ed.) Little & Brown, 1996

P.49 掲載の参考文献

• 1) 向野賢治 (訳), 小林寛伊 (監訳):隔離予防策の原理. INFECTION CONTROL 別冊「病院における隔離予防策のためのCDC最新ガイドラインJ. メディカ出版, 1996, pp.33-37

• 2) Sepkowitz, K. A.:Occupationally acquired infections in health care workers. Part 1. Ann. Intern. Med. 15:826-834, 1996
  pubmed

• 3) Center for Disease Control and Prevention:Guidelines for preventing the transmission of tuberculosis in health-care facilities, 1994. MMVVR:1-132, 1994 and Federal Register 59:54242-54303, 1994

• 4) Center for Disease Control and Prevention:Guidelines for prevention of Nosocomial Pneumonia-Legionnaires Disease 39:28-34, 1994

• 5) Center for Disease Control and Prevention:Guideline for Prevention of Nosocomial Pneumonia-Aspergillosis 39:34-37, 1994

• 6) Leclair, J. M., Zaia, J. A., Levin, M. J. et al.:Airborne transmission of chickenpox in a hospital. N. Engl. J. Med. 302:450-453, 1980

• 7) Gustafson, T. L., Lavely, G. B., Brawner, E. R. et al.:An outbreak of airborne nosocomial varicella. Pediatrics 70:550-556, 1982
  pubmed

• 8) Center for Disease Control and Prevention:Exposure of passengers and flight crew to Mycobacterium tuberculosis on commercial aircraft, 1992-1995. IVMWR 44:137-140, 1995

• 9) Center for Disease Control and Prevention:Probable transmission of multidrug-resistant tuberculosis in a correctional facility-California. NMWR 42:48-51, 1993

• 10) 武田誠司, 多々良一郎, 向野賢治ほか:全身性エリテマトーデスに併発したクリプトコックス髄膜炎のFluconazole による1治験例. 感染症誌68:1417-1420, 1994

• 11) Center for Disease Control and Prevention:Guideline for Prevention of Nosocomial Pneumonia-Influenza 39:40-43, 1994

• 12) French, G.:Contamination of doctors:and nurses:pens with nosocomial pathogens. Lancet 351:213, 1998
  pubmed

• 13) Hall, C. B., Douglas, R. G. Jr.:Modes of transmission of respiratory syncytial virus. J. Pediatr. 99:100-103, 1981
  pubmed

• 14) 加藤直樹, 加藤はる:Clostridium difficile. INFECTION CONTROL 7:892-896, 1998

• 15) McFarland, L. V., Mulligan, M. E., Kwok, R. Y. et al.:Nosocomial acquisition of Clostridium difficile Infection. N. Engl. J. Med. 320:204-210, 1989
  pubmed

• 16) 小花光夫:疥癬感染の事例. メディカルクレンリネス&サニテーション14:25-35, 1992

P.65 掲載の参考文献

• 1) 古川恵一:抗生物質によってもたらされる弊害. 臨床診断のピットフォール. 医歯薬出版, 1988, pp. 234-239

• 2) Chandrasekar, P. H., Brown, W. J.:Clinical issues of blood cultures. Arch. Intern. Med. 154:841-849, 1994
  pubmed

• 3) 中村良子:ウイルス感染症の血清学的診断法検査微生物学 (II) 臨床病理 臨時増刊:29-108, 1998

• 4) 飯沼由嗣:非細菌性肺炎. 救急医学22:1319-1322, 1998

• 5) Sackett, D. L.:Evidence-based medicine. How to practice and teach EBM. Churchill Livingstone, New York, 1997

• 6) ATS Statement:Guidelines for the Initial Management of Adults with Community-acquired Pneumonia:Diagnosis, Assessment of Severity, and Initial Antimicrobial Therapy. Am. Rev. Respir. Dis. 148:1418-1426, 1993

• 7) ATS Statement:Hospital-acquired Pneumonia in Adults:Diagnosis, Assessment of Severity, Initial Antimicrobial Therapy, and Preventative Strategies. Am. J. Respir. Crit. Care Med. 153:1711-1725, 1995

• 8) ATS Statement:Treatment of Tuberculosis and Tuberculosis Infection in Adults and Children. Am. J. Respir. Crit. Care Med. 149:1359-1374, 1994

• 9) ATS Statement:Diagnosis and Treatment of Disease Caused by Nontuberculous Mycobacteria. Am. J. Respir. Crit. Care Med. 156:S1-S25, 1997

• 10) British Thoracic Society:Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. Br. J. Hosp. Med. 49:346-350, 1993
  pubmed

• 11) Ishida, T., Hashimoto, T., Arita, M. et al.:Etiology of community-acquired pneumonia in hospitalized patients:a 3-year prospective study in Japan. Chest 114:1588-1593, 1998
  pubmed

II 抗菌薬の基礎知識

P.82 掲載の参考文献

• 1) 八木澤守正 (監修):最新「抗菌薬」一覧表. Medicament News第1626号付録. 株式会社ライフ・サイエンス, 1999

• 2) 八木澤守正:抗菌薬の種類と適応菌種. 最新・感染症治療指針99年改訂版. (島田馨監修) 医薬ジャーナル社, 1999, pp. 14-51

• 3) 日本医薬情報センター(編):日本医薬品集. 医療薬第22版1998-1999. 薬業時報社, 1998

P.90 掲載の参考文献

• 1) Spratt, B. G.:Penicillin-binding proteins and the future of beta-lactam antibiotics. The Seventh Fleming Lecture. J. Gen. Microbiol. 129:1247-1260, 1983
  pubmed

• 2) Matsuhashi, M., Wachi, M., Ishino, F.:Machinery for cell growth and division:penicillin-binding proteins and other proteins. Res. Microbiol. 141:89-103, 1990
  pubmed

• 3) Romeis, T., Holtje, J. V.:Penicillin-binding protein 7/8 of Escherichia coli is a DD-endopeptidase. Eur. J. Biochem. 224:597-604, 1994

• 4) Gellert, M.:DNA topoisomerases. Annu. Rev. Biochem. 50:879-910, 1981
  pubmed

• 5) Kato, J., Nishimura, Y., Imamura, R. et al.:New topoisomerase essential for chromosome segregation in E. coli. Cell 63:393-404, 1990

• 6) Shen, L. L., Mitscher, L. A., Sharma, P. N. et al.:Mechanism of inhibition of DNA gyrase by quinolone antibacterials:a cooperative drug-DNA binding model. Biochemistry 28:3886-3894, 1989
  pubmed

• 7) Hoshino, K., Sato, K., Akahane, K. et al.:Significance of the methyl group on the oxazine ring of ofloxacin derivatives in the inhibition of bacterial and mammalian type II topoisomerases. Antimicrob. Agents Chemother. 35:309-312, 1991

• 8) Morrissey, K., Hoshino, K., Sato, K. et al.:Mechanism of differential activities of ofloxacin enantiomers. Antimicrob. Agents Chemother. 40:1775-1784, 1996

• 9) Hoshino, K., Kitamura, A., Morrissey, 1. et al.:Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrob. Agents Chemother. 38:2623-2627, 1994

• 10) Tanaka, M, Onodera, Y., Uchida, Y. et al.:Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus. Antimicrob. Agents Chemother. 41:2362-2366, 1997
  pubmed

• 11) 谷本弘一, 小澤良之, 富田治芳, 池 康嘉:グリコペプチド系薬剤とグリコペプチド耐性腸球菌. 月刊薬事 41:1807-1814, 1999

• 12) 橋本 一:ホスホマイシンの使用状況・抗菌作用点・他剤との併用効果. 第28回薬剤耐性菌シンポジウム講演記録. 1999, pp. 40-44

• 13) Pestka, S.:Inhibition of ribosome functions. Annu. Rev. Microbiol. 25:487, 1971

• 14) 善養寺浩, 長田恭明:化学療法剤作用の生化学. 近代出版, 東京, 1978, pp. 119-149

• 15) Kobayashi, H.:Airway biofilm disease:clinical manifestations and therapeutic possibilities using macrolides. J. Infect. Chemother. 1:1-15, 1995

• 16) 田代亨, 竹野幸男, 上田直行ほか:マクロライド系抗生剤のヒト副鼻腔粘膜繊毛運動に及ぼす影響. 第5回マクロライド新作用研究会記録集. 1998, pp. 5-7

• 17) 田中信夫:アミノ配糖体薬の薬効・薬理. アミノ配糖体. (上田泰編) 南江堂, 東京, 1985, pp. 33-43

• 18) Albert, A.:薬剤作用の制御 その分子的基礎. 選択毒性 第7版. (秋野美樹, 水谷純也編) 学会出版センター, 東京, 1994, pp. 109-175

P.112 掲載の参考文献

• 1) 山口恵三:抗菌薬感受性試験. 抗微生物薬の基礎知識. (山口恵三編, 桑原章吾監) 南山堂, 東京, 1998, pp. 235-250

• 2) 古谷信彦, 山口恵三:原因菌の検索方法. モダンフィジシャン18:573-577, 1998

• 3) Geckler, R. W., Cremillion, D. H., McAllister, C. K. et al.:Microscopic and bacteriological comparison of paired sputa and transtracheal aspirates. J. Clin. Microbiol. 6:396-399, 1977

• 4) 清水喜八郎:抗菌薬の治療計画. 新抗菌薬の使い方. (清水喜八郎編) 三共, 東京, 1999, pp. 1-12

• 5) Armstrong, D.:Empiric therapy for the immunocompromised host. Rev. Infect. Dis. 13 (Suppl. 9):S763-S769, 1991

• 6) 那須 勝:抗生物質の臓器到着性. Medical Practice 12:48-51, 1995

• 7) 松本哲哉, 山口恵三:抗生物質の血中濃度測定. 薬物動態とその臨床的意義. Medical Practice 12:58-62, 1995

• 8) 戸塚恭一:抗菌薬療法の新しい考え方. 臨床医24:1077-1081, 1998

• 9) 館田一博, 山口恵三:抗生物質の有効指標としての抗菌薬感受性試験. 総合臨床44:1525-1529, 1995

• 10) 松本文夫, 森田雅之, 佐藤康信:抗生物質の投与ルート, 投与法, 投与量および投与期間の設定の目安と ポイント. Medical Practice 12:29-34, 1995

• 11) 大西明弘, 田中昭二, 戸田剛太郎:肝不全・腎不全と抗生物質, 総合臨床44:1600-1605, 1995

• 12) 堀 誠治, 佐藤淳子:腎機能低下時の抗菌薬の使い方. モダンフィジシャン18:595-601, 1998

• 13) Favero, A. D., Bucaneve, G., Menichetti, F.:Empiric monotherapy in neutropenia:a realistic goal? Scand. J. Infect. Dis. Suppl. 96:34-37, 1995

• 14) 山口恵三:主要感染症における第一選択薬をどのように考えるか. 内科74:1005-1010, 1994

• 15) Moellering, R. C. Jr.:Principles of antiinfective therapy. Principles and practice of infectious diseases. (Mandell, G. L, Bennett, J. E., Dolin, R.) Churchill livingstone, New York, 1995, pp. 199-212

III 微生物検査の基礎知識

P.125 掲載の参考文献

• 1) 平洋一:感染症診断の進め方. 臨床検査42:1213-1227, 1998

• 2) 菅野治重:起炎菌の検出. 検査と技術24:26-27, 1996

• 3) 浅利誠志:迅速微生物検査法-抗原および毒素の検出 毒素. Medical Technology 27:255-259, 1999
  Medical*Online

• 4) 山口恵三:抗菌薬感受性試験. 臨床検査42:1251-1268, 1998

• 5) 小川祐司, 池田明人, 山中喜代治:免疫学的細菌検査. 検査と技術27:868-871, 1999

• 6) 山中喜代治:検査の作業手順を確立しよう 細菌検査. 検査と技術26:167-170, 1998

P.144 掲載の参考文献

• 1) 山中喜代治:迅速検査としてのグラム染色-Bartholomew & Mittwer (B & M) 染色法を中心に. Medical Technology 23:205-213, 1995

• 2) 九州臨床検査精度管理研究会 (監):検鏡・塗布・菌集落観察の技術. 臨床細菌検査マニュアル. 日水製薬株式会社, 1994, pp. 24-25

• 3) Nugent, R. P., Krohn, M. A., Hillier, S. L.:Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J. Clin. Microbiol. 29:297-301, 1991
  pubmed

• 4) 島野敏司:妊娠時細菌性膣症の診断・治療. 産婦人科の実際47:95-102, 1998

• 5) 厚生省 (監):結核菌検査指針. 日本公衆衛生協会, 1979, pp. 16-20

• 6) 山根誠久:抗酸菌について-CDC勧告の実現をめざして. 臨床病理47:539-545, 1999

• 7) Centers for Disease Control and Prevention (CDC):Guidelines for preventing the Transmission of Mycobacterium tuberculosis in health care facilities. Morbid Mortal Weekly Rep 43:1-13, 1994

• 8) 阿部美知子, 鉢村和男, 内山幸信, 久米光:深在性真菌症の微生物学的検査. 臨床検査43:176-184, 1999

• 9) 阿部美知子, 鉢村和男, 内山幸信, 久米光:Pneumocystis cariniiによるカリニ肺炎. カラーアトラス微生物検査. Medical Technology別冊:110-113, 1996

• 10) 赤尾信吉, 赤塚由子, 朝隈蓉子ほか:染色法のすべて. Medical Technology別冊:316-319, 1996

• 11) 竹内勤:ジアルジア感染症. 感染症症候群II 日本臨床 別冊:427-429, 1999

• 12) 井関基弘, 木俣勲:クリプトスポリジウム症・サイクロスポーラ症. 臨床検査42:541-546, 1998

• 13) 海老沢功:輸入マラリア-現状と検査法の進歩. 臨床検査36:869-874, 1992

• 14) 川本文彦, 劉 慶, 水野さほ子 ほか:アクリジンオレンジ染色によるマラリアの迅速診断法. 臨床検査42:243-247, 1998

P.152 掲載の参考文献

• 1) 菅野治重:院内感染を起こしやすい微生物. 臨床と微生物26:363-368, 1999

• 2) 小栗豊子:患者検体からの病原微生物の検査法材料別臨床微生物検査ハンドブック. (小栗豊子編) 三輪書店, 東京, 1997, pp. 26-31

• 3) Jousimies-somer, H. R., Summanen, P. H., Finegold, S. M.:Bacteroides, Porphyromonas, Prevotella, Fsobacterium, and other anaerobic gram-negative bacteria. Manual of clinical microbiology, 6th ed. 1995, PP. 603-620

• 4) 坂崎利一 (監訳):コンピュータによる細菌の同定. 医学細菌同定の手引き (第3版) . 近代出版, 東京, 1993, pp. 202-206

P.163 掲載の参考文献

• 1) Mahony, J. B., Chernesky, M. A.:Immnoassays for Diagnosis of infectious Diseases. Manual of Clinical Microbiology 7th edition. Washington, D. C., ASM, 1999, pp. 202-213

• 2) 中村正夫 (編著):感染症の免疫血清学的検査. ライフ・サイエンス, 東京, 1990

• 3) 中村良子:感染症の免疫血清検査-細菌・真菌感染症. 臨床看護21:956-963, 1995

• 4) 島川宏一:今日使用可能な迅速診断法の種類とそれらの臨床的意義-培養法によらない迅速診断法 (24時間以内) 細菌性疾患を対象に. JARMAM 7:45-50, 1995

• 5) 浅利誠志:免疫学的検査法 (凝集法, EIA法など) . 検査微生物学 (1)-細菌, 真菌, クラミジア, リケッチア感染症の検査診断:31-35, 1997

• 6) 小川祐司, 池田明人, 山中喜代治:免疫学的検査a) 細菌感染症. 検査と技術21:868-963, 1995

• 7) 中村良子:感染症の簡易検査. Medical Technology 27:1033-1037, 1999
  Medical*Online

• 8) Tang, Y. W., Persing, D. H.:Molecular Detection and Identification of Microorganisims:Manual of Clinical Microbiology 7th edition. Washington, D. C., ASM, 1999, pp. 215-244

• 9) Persing, D. H. et al.:Diagnostic molecular microbiology, Principles and Amplications. ASM, 1993

• 10) 市瀬正之ほか:DNAプローブ法によるC. trachomatisならびに淋菌検出に関する基礎的および臨床的検討. 臨床と微生物19:527-533, 1992

• 11) Griffin, H. G.:PCR TECHNOLOGY Currents Innovations:249-256, 1994

• 12) 関谷剛男ほか:鋳型DNAの調製. PCR法最前線:453-469, 1996

• 13) 谷口武利 (編):PCRの基本. PCR実験ノート. 1997, pp. 12-35

• 14) 島川宏一:結核菌の遺伝子検査とその適応. 検査と技術23:1033-1038, 1995

• 15) Limberger, R. J., Biega, R., Evancoe, A. et al.:Evaluation of culture and the Gen-Probe 2 assay for detection of Neisseria gonorrhoeae and Chlamydia trachomatisis endocervical specimens transported to a state health laboratory. J. Clin. Microbiol. 30:1162-1166, 1992

P.172 掲載の参考文献

• 1) 川上小夜子, 斧康雄, 宮澤幸久:感受性検査法の現状と課題. 日臨微誌9:59-64, 1999

• 2) 日本化学療法学会抗菌薬感受性測定法検討委員会報告:呼吸器感染症および敗血症におけるブレイクポイント. Chemotherapy 42:906-914, 1994

• 3) 日本化学療法学会抗菌薬感受性測定法検討委員会報告:尿路感染症における抗菌薬のブレイクポイント. 日本化学療法学会雑誌45:711-726, 1997

• 4) NCCLS:Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Fourth Edition; Approved Standard, NSSLS document M7-A4. NCCLS, Wayne Pennsylvania, 1997

• 5) NCCLS:Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard-Fourth Edition M11-A4, NSSLS document M7-A4. NCCLS, Wayne Pennsylvania, 1997

• 6) NCCLS:Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard M27-A, NSSLS document M7-A4. NCCLS, Wayne Pennsylvania, 1997

• 7) 日本化学療法学会抗菌薬感受性測定法検討委員会報告 (1989) (委員長:五島瑳智子):微量液体希釈法によるMIC測定法 (微量液体希釈法) -日本化学療法学会標準法. Chemotherapy 38:102-105, 1990

• 8) 抗菌薬感受性測定法検討委員会報告 (1992) (委員長:斎藤厚):1. 微量液体希釈法によるMIC測定法 (日本化学療法学会標準法) の一部修正, II. (追補1) 栄養要求性の厳しい菌種を対象とした培地の調整 および感受性測定法, III. 微量液体希釈法による嫌気性菌のMIC測定法-日本化学療法学会標準法. Chemotherapy 41:184-189, 1993

• 9) NCCLS:Performance Standards for Antimicrobial Susceptibility Testing; Ninth Informational Supplement M100-S9. NCCLS, Wayne Pennsylvania, 1999

• 10) 斎藤厚:呼吸器感染症におけるブレイクポイントの利用の仕方. 化学療法の領域13:551-559, 1997

• 11) NCCLS:Performance Standards for Antimicrobial Disk Susceptibility Tests-Sixth Edition; Approved Standard, NSSLS document M2-A6. NCCLS, Wayne Pennsylvania, 1997

• 12) 相原雅典:ディスク拡散法. 検査と技術増刊号-感染症検査実践マニュアル. 医学書院, 東京, 1996, pp. 239-241

• 13) 菅野治重:抗生物質の抗菌力判定法とその読み方. 抗生物質療法ガイド. 文光堂, 東京, 1996, pp. 52-57

• 14) 昭和薬品化工:昭和ディスクユーザーズ・マニュアル. 昭和薬品化工, 東京, 1990, pp. 27

IV 新興感染症，再興感染症

P.181 掲載の参考文献

• 1) WHO:The World Health Report 1996. Fighting disease fostering development, Geneva, 1996

• 2) Satcher, D.:Emerging infections:Getting ahead of the curve. Emerg. Infect. Dis. 1:1-6, 1995
  pubmed

• 3) Liu, H. H.:Antibiotic resistance in bacteria. A current and future problem. Adv. Exp. Med. Biol. 455:387-396, 1999
  pubmed

• 4) WHO:Emerging infectious diseases:Memorandum from a WHO meeting. Bull World Health Organ. 72:845, 1994
  pubmed

• 5) WHO:World Health Assembly. Communicable diseases prevention and control:new, emerging, and re-emerging infectious diseases. WHO Doc. WHA 48. 13, May 12, 1995

• 6) Fidler, D. P.:Globalization, international law, and emerging infectious diseases. Emerg. Infect. Dis. 4:353, 1998

• 8) Henderson, D. A.:About the first national symposium on medical and public response to bioterrorism. Emerg. Infect. Dis. 5:491, 1999

• 9) 厚生省保健医療局結核感染症課 (監):感染症の予防及び感染症の患者に対する医療に関する法律. 中央法規出版, 1999

• 10) 感染症の診断・治療研究会:感染症の診断・治療ガイドライン. (日本医師会感染症危機管理対策室厚生省保健医療局結核感染症課監) 日医会誌122 (10), 1999

• 11) 森亨:結核. 感染症の診断治療のガイドライン. 日医会誌122:268, 1999

• 12) 吉山崇, 森亨:結核. Med. Pract. 16:1827, 1999
  Medical*Online

• 13) 厚生省健康政策局指導課 (監):院内感染対策. Q & A現場からのMRSA感染対策の疑問に答える. ヘルス出版, 1997

P.191 掲載の参考文献

• 1) Ubukata, K. et al.:Occurrence of aB-lactam inducible-penicillin-binding proteins in methicillin resistant Staphylococci. Antimicrob. Agents Chemother. 27:851-857, 1985

• 2) Utsui, Y. et al.:Role of an altered penicillin-binding proteins in methicillin-resistant and cephem-resistant S. aureus. Antimicrob. Agents Chemother. 28:397-403, 1985
  pubmed

• 3) 賀来満夫, 吉田良滋:耐性菌のvirulence factor. 日本臨床52:322-326, 1994

• 4) Garner, J. S.:The Hospital Infection Control Practices Advisery Committee:Guideline for Isolation Precautions in Hospitals. Infect. Control Hosp. Epidemiol. 17:54-80, 1996

• 5) 賀来満夫ほか:総合病院における環境管理と検査. 日本臨床微生物学雑誌6:59-62, 1996

• 6) 賀来満夫:感染制御の重要性と今後の課題. 聖マリアンナ医科大学雑誌25:249-259, 1997

• 7) Hiramatsu, K., Hanaki, H., Ino, T. et al.:Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 11:586-599, 1997

• 8) 江藤和裕ほか:バンコマイシンのTDM:3点採血に基づくSawchuck-Zaske法によるパラメータの設定とその値を事前情報とするPEDAによるBayesian法の適用. TDM研究12:47-52, 1995

• 9) 賀来満夫:MRSA感染症. PROGRESS IN MEDICINE 11:2655-2660, 1998
  Medical*Online

• 10) 松山賢治:TDMを考慮したMRSA用抗菌薬の適正使用. INFECTION CONTROL 8:838-841, 1999

P.201 掲載の参考文献

• 1) Brisson-Noel, A., Dutka-Malen, S., Molinas, C. et al.:Cloning and heterospecific expression of the resistance determinant vanA encoding high-level resistance to glycopeptides in Enterococcus faecium BM4147. Antimicrob. Agents Chemother. 34 (5):924-927, 1990
  pubmed

• 2) Evers, S., Sahm, D. F., Courvalin, P.:The vanB gene of vancomycin-resistant Enterococczas faecalis V583 is structurally related to genes encoding D-Ala:D-Ala ligases and glycopeptide-resistance proteins VanA and VanC. Gene 124 (1):143-144, 1993
  pubmed

• 3) Leclercq, R., Dutka-Malen, S., Duval, J., Courvalin, P.:Vancomycin resistance gene vanC is specific to Enterococcus gatlinarum. Antimicrob. Agents Chemother. 36:2005-2008, 1992
  pubmed

• 4) Perichon, B., Reynolds, P., Courvalin, P.:VanD-type glycopeptide-resistant Enterococcus faecium BM4339. Antimicrob. Agents Chemother. 41 (9):2016-2018, 1997
  pubmed

• 5) 厚生省生活衛生局乳肉衛生化:食肉より分離された腸球菌の高度バンコマイシン耐性に関する調査, 研究報告. 「食肉中の腸球菌のバンコマイシン耐性菌に関する調査研究班」 (班長:群馬大学医学部. 池教授)

• 6) Hospital infection control practice advisory committee:Recommendations for preventing the spread of vancomycin resistance. MMWR 44 (RR-12):1-13, 1995

• 7) 佐竹幸子, 河原いくみ:バンコマイシン耐性菌の伝搬防止のためのCDCガイドライン. Infection control別冊, メディカ出版, 大阪, 1997, pp. 1-73

• 8) Reynolds, P. E, Snaith, H. A., Maguire, A. J. et al.:Analysis of peptidoglycan precursors in vancomycin-resistant Enterococcus gallinarum BM4174. Biochem. J. 301 (Pt 1):5-8, 1994

• 9) Handwerger, S., Pucci, M. J., Volk, K. J. et al.:The cytoplasmic peptidoglycan precursor of vancomycin-resistant Enterococcus faecalis terminates in lactate. J. Bacteriol. 174 (18):5982-5984, 1992
  pubmed

• 10) Arthur, M., Molinas, C., Bugg, T. D. et al.:Evidence for in vivo incorporation of D-lactate into peptidoglycan precursors of vancomycin-resistant enterococci. Antimicrob, Agents Chemother. 36 (4):867-869, 1992
  pubmed

• 11) de Jonge, B. L., Handwerger, S., Gage, D.:Altered peptidoglycan composition in vancomycin-resistant Enterococcus faecalis. Antimicrob. Agents Chemother. 40 (4):863-869, 1996
  pubmed

• 12) Billot-Klein, D., Shlaes, D., Bryant, D. et al.:Peptidoglycan structure of Enterococcus faecium expressing vancomycin resistance of the VanB type. Biochem. J. 313 (Pt 3):711-715, 1996

• 13) Casadewall, B., Courvalin, P.:Characterization of the vanD glycopeptide resistance gene cluster from Enterococcus faecium BM4339. J. Bacteriol. 181 (12):3644-3648, 1999
  pubmed

• 14) 花木秀明:VREの新規検出法. 化学療法の領域15 (4):60-63, 1999

• 15) Daniel, A. B., Dudley, H. W., Michael, N. G., David, J. C. K.:Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics. Antimicrob. Agent Chemother. 39:781-785, 1995

• 16) Arthur, M., Courvalin, P.:Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob. Agents Chemother. 37:1563-1571, 1993
  pubmed

• 17) Rao, J., Yan, L., Lahiri, J. et al.:Binding of a dimeric derivative of vancomycin to L-lys-D-ala-D-lactate in solution and at a surface. Chem. Biol. 6 (6):353-359, 1999

• 18) Nieto, M., Perkins, H. R.:Modifications of the acyl-D-alanyl-D-alanine terminus affecting complex-formation with vancomycin. Biochem. J. 123:789-803, 1971
  pubmed

• 19) Courvalin, P.:Resistance of enterococci to glycopeptides. Antimicrob. Agent Chemother. 34:2291-2296, 1991

• 20) Arthur, M., Reynolds, P., Courvalin, P.:Glycopeptide resistance in enterococci. Trends Microbiol. 4:401-407, 1996
  pubmed

• 21) Leclercq, R., Derlot, E., Duval, J., Courvalin, P.:Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. . N. Engl. J. Med. 319:157-161, 1988
  pubmed

• 22) Leclercq, R., Derlot, E, Weber, M. et al.:Transferable vancomycin and teicoplanin resistance in Enterococcus faecium. Antimicrob. Agents Chemother. 33:10-15, 1989
  pubmed

• 23) Bugg, T. D., Wright, G. D., Dutka-Malen, S. et al.:Molecular basis for vancomycin resistance in Enterococcus faecium BM4147:biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. Biochemistry 30 (43):10408-10415, 1991
  pubmed

• 24) Arthur, M., Molinas, C., Dutka-Malen, S., Courvalin, P.:Structural relationship between the vancomycin resistance protein VanH and 2-hydroxycarboxylic acid dehydrogenases. Gene 103 (1):133-134, 1991
  pubmed

• 25) Bugg, T. D., Dutka-Malen, S., Arthur, M. et al.:Identification of vancomycin resistance protein VanA as a D-alanine:D-alanine ligase of altered substrate specificity. Biochemistry 30 (8):2017-2021, 1991

• 26) Reynolds, P. E., Depardieu, F., Dutka-Malen, S. et al.:Glycopeptide resistance mediated by enterococcal transposon Tn1546 requires production of VanX for hydrolysis of D-alanyl-D-alanine. Mol. Microbiol. 13 (6):1065-1070, 1994
  pubmed

• 27) Arthur, M., Depardieu, F., Snaith, H. A. et al.:Contribution of VanY D, D-carboxypeptidase to glycopeptide resistance in Enterococcus faecalis by hydrolysis of peptidoglycan precursors. Antimicrob. Agents Chemother. 38 (9):1899-1903, 1994
  pubmed

• 28) Wright, G. D., Molinas, C., Arthur, M. et al.:Characterization of vanY, a D,D-carboxypeptidase from vancomycin-resistant Enterococcus faecium BM4147. Antimicrob. Agents Chemother. 36 (7):1514-1518, 1992

• 29) Quintiliani, R. Jr., Evers, S., Courvalin, P.:The vanB gene confers various levels of self-transferable resistance to vancomycin in enterococci. J. Infect. Dis. 167:1220-1223, 1993
  pubmed

• 30) Evers, S., Courvalin, P.:Regulation of VanB-type vancomycin resistance gene expression by the VanS (B)-VanR (B) two-component regulatory system in Enterococcus faecalis V583. J. Bacteriol. 178 (5):1302-1309, 1996
  pubmed

• 31) Dutka-Malen, S., Molinas, C., Arthur, M., Courvalin, P.:Sequence of the vanC gene of Enterococcus gallinarum BM4174 encoding a D-alanine:D-alanine ligase-related protein necessary for vancomycin resistance. Gene 112 (1):53-58, 1992

• 32) Healy, V. L, Park, 1. S., Walsh, C. T.:Active-site mutants of the VanC 2 D-alanyl-D-serine ligase, characteristic of one vancomycin-resistant bacterial phenotype, revert towards wild-type D-alanyl-D-alanine ligases. Hem. Biol. 5 (4):197-207, 1998

• 33) Elisha, B. G., Courvalin, P.:Analysis of genes encoding D-alanine:D-alanine ligase-related enzymes in Leuconostoc mesenteroides and Lactobacillus spp. Gene 152 (1):79-83, 1995
  pubmed

P.210 掲載の参考文献

• 1) Calderwood, S. B. et al.:Proposed new nomenclature for SLT (VT) family. ASM News 62:118-119, 1996

• 2) 飯田哲也, 本田武司:腸管出血性大腸菌0-157の病原遺伝子. 遺伝子医学2:315-320, 1999

• 3) 本田武司:病気と細菌毒素. 化学同人, 京都, 1994, pp. 81-89

• 4) 本田武司:腸管出血性大腸菌研究の動向. 学術月報52:152-156, 1999

• 5) 堺市学童集団下痢症対策本部:堺市学童集団下痢症報告書, 1997

P.221 掲載の参考文献

• 1) McDade, J. E., Shepard, C. C., Fraser, D. W. et al.:Legionnaires:disease:Isolation of a bacterium and demonstration of its role in other respiratory diseases. N. Engl. J. Med. 297:1197-1203, 1977
  pubmed

• 2) Memorandum from a WHO meeting:Epidemiology, prevention and control of legionellosis. Bull WHO 68:155-164, 1990
  pubmed

• 3) 小出道夫, 斎藤厚, 山城裕子ほか:微量定量凝集法によるLegionella感染症の診断-間接蛍光抗体法との比較. 感染症誌70:1254-1258, 1996

• 4) 新垣紀子, 比嘉 太, 小出道夫ほか:レジオネラ肺炎に対する早期診断法としての尿中抗原検出法の意義. 感染症誌73:421-428, 1999

• 5) 比嘉 太:新興・再興感染症の臨床-レジオネラ. Medical Digest 47:21-25, 1998

• 6) 斎藤厚:9. 専門医を目指すケース・メソッド・アプローチ case 1発熱と意識レベルの低下を来した58歳男性呼吸器疾患. (中田紘一郎編) 日本医事新報社, 東京, 1998, pp. 1-10

P.232 掲載の参考文献

• 1) Chiba, Y.:Significance of endogenous reactiyation. 30 year follow-up of tuberculin positive converters. Bull. Int. Union Tuberc. 49:321-324, 1974

• 2) 青木正和:結核疫学の展望. 発病論 (前編) . 結核58:371-378, 1983

• 3) 青木正和:ビジュアルノート結核基礎知識. 結核予防会, 1998

• 4) 青木正和:ビジュアルノート結核その現状と今後. 結核予防会, 1998

• 5) 毛利昌史, 四元秀毅, 倉島篤行:結核Up to date. 南江堂, 1999

P.241 掲載の参考文献

• 1) Guay, L. A., Musoke, P., Fleming, T. et al.:Intrapartum and neonatal single-dose nevirapine with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda:HIVNET 012 randomised trial. Lancet 354 (9181):795-802, 1999
  pubmed

• 2) Public Health Service Guidelines for the Management of Health-Care Worker:Exposures to HIV and Recommendations for Postexposure Prophylaxis. MMWR 4711-28, 1998

• 3) Jacquez, J., Koopman, J., Simon, C. et al.:Role of the primary infection in epidemics of HIV infection in gay cohorts. J. Acquir. Immune Defic. Syndr. 7:1169-1184, 1994
  pubmed

• 4) Rong, L, William, A. P., Sunny, C. et al.:Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed indivisuals to HIV-1 infection. Cell 86:367-377, 1996

• 5) Deacon, N. J., Tsykin, A., Solomon, A. et al.:Genomic stracture of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270:988-991, 1995

• 6) Fichtenbaum, C. J., Woeltje, K. F., Powderly, W. G.:Serious Pseudomonas aeruginosa infections in patients infected with human immunodeficiency virus:a case-control study. Clin. Infect. Dis. 19:417-422, 1994

V 病院感染対策

P.252 掲載の参考文献

• 1) Garner, J. S., HICPAC:Guideline for isolation precautions in hospitals. Am. J. Infect. Control Hosp. Epidemiol. 24:24-52, 1996

• 2) Kluytmans, J. A., Mouton, J. W., Vanden Bergh, M. F. et al.:Reduction of surgical-site infections in cardiothoracic surgery by elimination of nasal caniage of Staphylococcus aureus. Infect. Control Hosp. Epidemiol. 17:780-785, 1996
  pubmed

• 3) Johnson, A. P.:Intermediate vancomycin resistance in Staphylococcus aureus; a major threat or a minor inconvenience? J. Antimicrob. Chemother. 42:289-591, 1998
  pubmed

• 4) Lam, S., Singer, C., Tucci, V. et al.:The challenge of vancomycin resistant enterococci; A clinical and epidemiologic study. Am. J. Infect. Control 23:170-180, 1995
  pubmed

• 5) CDC:Geographic variation in penicillin resistance in Staphylococcus pneumoniae-selected sites, United States, 1997. MMWR 48 (30):656-661, 1999

• 6) CDC:Tuberculosis morbidity, United States, 1997. MMWR 47 (13):253-257, 1998
  pubmed

• 7) Mangram, A. J., Horan, T. C., Pearson, M. L. et al.:Guideline for prevention of surgical site infection, 1999. Infect. Control Hosp. Epidemiol. 20:247-278, 1999

• 8) 大久保憲:消毒・滅菌の実際. 消毒と滅菌のガイドライン. (小林寛伊編) へるす出版, 東京, 1999, pp. 8-35

• 9) 大久保憲, 新太喜治, 小林寛伊ほか:電解酸性水に関する調査報告. 手術医学15:508-520, 1994

• 10) Gamer, J. S., Favero, M. S.:Guideline for handwashing and hospital environmental control, 1985. Am. J. Infect. Control 14:110-126, 1986

P.260 掲載の参考文献

• 1) 矢野邦夫, 浦野美恵子:HIV院内感染対策-HIVに関する職務上および院内感染予防対策. 日本医学館, 1997, pp. 1-4

• 2) Centers for Disease Control:Recommendations for prevention of HIV transmission in health-care settings. MMVVR 36:IS-18S, 1987
  pubmed

• 3) Centers for Disease Control Update:Universal precautions for prevention of transmission of HIV, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR 37:377-382, 387-388, 1998

• 4) 労働省労働衛生課 (監訳):血液感染性病原体への職業的曝露. 米国労働省労働安全衛生局による基準. 社団法人全国労働衛生団体連合会, 1994, pp. 63-69

• 5) Centers for Disease Control:Guideline for Isolation Precautions in Hospitals. 1997

• 6) 洪愛子 (訳):APIC Guideline for Hand washing and Hand Antisepsis in Health Care Settings. ジョンソン・エンド・ジョンソンメディカル株式会社, 1997

P.281 掲載の参考文献

• 1) 矢野邦夫, 浦野美恵子:院内感染対策ガイド. 米国疾病管理センター(CDC) による科学的対策. 日本医学館, 1998, pp. 106-112

• 2) 浦野美恵子:医療手技および器具に関する院内感染対策. 血管内カテーテルの管理について. Expert Nurse Vol. 15 No. 7. 1999, pp. 92-97

P.290 掲載の参考文献

• 1) Mangram, A. J., Horan, T. C., Pearson, M, L, et al.:Guideline for Prevention of Surgical Site Infection, 1999. Am. J. Infect. Control 27:97-132, 1999
  pubmed

• 2) Horan, T. C., Gaynes, R. P., Martone, W. J. et al.:CDC definitions of nosocomial surgical site infections, 1992:a modification of CDC definitions of surgical wound infections. Infect. Control Hosp. Epidemiol. 13:606-608, 1992
  pubmed

• 3) Gordon, S. M., Serkey, J. M., Barr, C. et al.:The relationship between glycosylated hemoglobin (HgA1c) levels and postoperative infections in patients undergoing primary coronary artery bypass surgery (CABG) [abstract]. Infect. Control Hosp. Epidemiol. 18 (No. 5, Part 2):29 (58), 1997

• 4) Nagachinta, T., Stephens, M., Reitz, B., Polk, B. F.:Risk factors for surgical-wound infection following cardiac surgery. J. Infect. Dis. 156:967-973, 1987
  pubmed

• 5) Kluytmans, J. A., Mouton, J. W., Ijzerman, E. P. et al.:Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. J. Infect. Dis. 171:216-219, 1995

• 6) Seropian, R., Reynolds, B. M.:Wound infections after preoperative depilatory versus razor preparation. Am J. Surg. 121:251-254, 1971
  pubmed

• 7) Masterson, B. J.:Cleansing the surgeon's hands. Scientific American Surgeon 2:3-9, 1996

• 8) Garner, J. S.:CDC guideline for prevention of surgical wound infections, 1985. Supercedes guideline for prevention of surgical wound infections published in 1982 (Originally published in 1995). Revised Infect. Control 7:193-200, 1986

P.295 掲載の参考文献

• 1) Fraser, D. W., Tsai, T. R., Oremstein, W. et al.:Legionnaires'disease:description of an epidemic of pneumonia. N. Engl. J. Med. 297:1189-1197, 1977

• 2) Hoge, C. W., Breiman, R. F.:Advances in the epidemiology and control of Legionella infections. Epidemiol. Rev. 13:329-340, 1991
  pubmed

• 3) Vickers, R. M., Yu, V. L., Hanna, S. S.:Determinants of Legionella pneumophila contamination of water distribution systems:15-hospital prospective study. Infect. Control 8:357-363, 1987
  pubmed

• 4) Alary, M. A., Joly, J. R.:Factors contributing to the contamination of hospital water distribution systems by Legionellae. J. Infect. Dis. 165:565-569, 1992

• 5) Alary, M. A., Joly, J. R.:Factors contributing to the contamination of hospital water distribution systems by Legionellae. J. Infect. Dis. 165:565-569, 1992

• 6) Plouffe, J. F, Para, M. F., Maher, W. E. et al.:Subtypes of Legionella pneumophila serogroup 1 associated with different attack rates. Lancet 2:649-650, 1983
  pubmed

• 7) Fraser, D. W.:Sources of legionellosis. Legionella:Proceedings of the 2nd International Symposium. ( Thornsberry, C., Balows, A., Feeley, J. C, Jakubowski, W. eds.) American Society for Microbiology, Washington, D. C., 1984, pp. 277-280

• 8) Dourmon, E., Bibb, W. F., Rajagopalan, P. et al.:Monoclonal antibody reactivity as a virulence marker for Legionella pneumophila serogroup 1 strain. J. Infect. Dis. 165:569-573, 1992

• 9) Mastro, T. D., Fields, B. S., Breiman, R. F. et al.:Nosocomial Legionnaires' disease and use of medication nebulizers. J. Infect. Dis. 163:667-670, 1991
  pubmed

• 10) Arnow, P. M., Chou, T., Weil, D. et al.:Nosocomial Legionnaires:disease caused by aerosolized tap water from respiratory devices. J. Infect. Dis. 146:460-467, 1982
  pubmed

• 11) Brundrett, G. W.:Guides on avoiding Legionnaires:disease. In:Legionella and Building Services. Butterworth Heineman, Oxford, 1992, pp. 346-373

• 12) Muraca, P. W., Yu, V. L., Goetz, A.:Disinfection of water distribution systems for Legionella:a review of application procedures and methodologies. Infect. Control Hosp. Epidemiol. 11:79-88, 1990
  pubmed

• 13) Bean, B., Moore, B. M., Sterner, B. et al.:Survival of influenza viruses on environmental surfaces. J. Infect. Dis. 146:47-52, 1982
  pubmed

• 14) Betts, R. F.:Amantadine and rimantadine for the prevention of influenza A. Semin. Respir. Infect. 4:304-310, 1989
  pubmed

• 15) Douglas, R. G.:Drug therapy:prophylaxis and treatment of influenza. N. Engl. J. Med. 322:443-450, 1990
  pubmed

• 16) Younkin, S. W., Betts, R. F., Roth, F. K. et al.:Reduction in fever and symptoms in young adults with influenza A/Brazil/78 H1N1 infection after treatment. Antimicrob. Agents Chemother. 23:577-582, 1983
  pubmed

• 17) Tominack, R. L, Hayden, F. G.:Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections. Infect. Dis. Clin. North Am. 1:459-478, 1987
  pubmed

• 18) Postma, J. U., Tilburg, W. V.:Visual hallucinations and delirium during treatment with amantadine (Symmetrel) . J. Am. Geriatr. Soc. 23:212-215, 1975

• 19) Falsey, A. R., Walsh, E. E., Betts, R. F.:Serologic evidence of respiratory syncytial virus infection in nursing home patients. J. Infect. Dis. 162:568-569, 1990
  pubmed

• 20) Hall, C. B.:The nosocomial spread of respiratory syncytial viral infections. Ann. Rev. Med. 34:311-319, 1983
  pubmed

P.300 掲載の参考文献

• 1) CDC:National Nosocomial Infections Study Report. Center for Disease Control, Atlanta, 1979, pp. 2-14

• 2) Martin, C. M., Bookrajian, E. N.:Bacteriuria prevention after indwelling urinary catheterization. Arch. Intern. Med. 110:703-711, 1962

• 3) Selden, R., Lee, S., Wang, W. L. L. et al.:Nosocomial Klebsiella infections:intestinal colonization as a reservoir. Ann. Intern. Med. 74:657-664, 1971

• 4) McLeod, J. W.:The hospital urine bottle and bedpan as reservoirs of infection by Pseudomonas. Lancet 1:394-395, 1958
  pubmed

• 5) Maki, D. G., Hennekens, C. H., Bennett, J. V. et al.:Nosocomial urinary tract infection with, Serratia marcescens:an epidemiologic study. J. Infect. Dis. 128:579-587, 1973

• 6) Kaslow, R. A., Lindsey, J. O., Bisno, A. L, Price, A.:Nosocomial infection with highly resistant Proteus rettgeri. Report of an epidemic. Am. J. Epidemiol. 104:278-286, 1976
  pubmed

• 7) Kass, E. H., Schneiderman, L. J.:Entry of bacteria into the urinary tract of patients with inlying catheters. N. Engl. J. Med. 256:556-557, 1957
  pubmed

• 8) Garibaldi, R. A., Burke, J. P., Britt, M. R. et al.:Meatal colonization and catheter-associated bacteriuria. N. Engl. J. Med. 303:316-318, 1980
  pubmed

• 9) Kunin, C. M., McCormack, R. C.:Prevention of catheter-induced urinary tract infections by sterile closed drainage. N. Engl. J. Med. 274:1155-1162, 1966
  pubmed

• 10) Garibaldi, R. A., Burke, J. P., Dickman, M. L., Smith, C. B.:Factors predisposing to bacteriuria during indwelling urethral catheterization. N. Engl. J. Med. 291:215-218, 1974
  pubmed

• 11) Turck, M., Goffe, B., Petersdorf, R. G.:The urethral catheters and urinary tract infection. J. Urol. 88:834-837, 1962
  pubmed

• 12) Kass, E. H.:A symptomatic infections of the urinary tract. Trans. Assoc. Am. Physicians 69:56-63, 1956

• 13) Steere, A. C., Mallison, G. F.:Handwashing practices for the prevention of nosocomial infections. Ann. Intern. Med. 83:683-690, 1975
  pubmed

• 14) Kunin, C. M.:Detection, prevention, and management of urinary tract infections. 3rd ed. Lea and Febiger, Philadelphia, 1979

• 15) Desautels, R. F., Walter, C. W., Graves, R. C. et al.:Technical advances in the prevention of urinary tract infection. J. Urol. 87:487-490, 1962

• 16) Warren, J. W., Platt, R., Thomas, K. J, et al.:Antibiotic irrigation and catheter-associated urinary tract infections. N. Engl. J. Med. 299:570-573, 1978

• 17) Britt, M. R., Garibaldi, R. A., Miller, W. A. et al.:Antimicrobial prophylaxis for catheter-associated bacteriuria. Antimicrob. Agents Chemother. 11:240-243, 1977
  pubmed

P.308 掲載の参考文献

• 1) The Hospital Infection Control Practices Advisory Committee, CDC:Guidelines for isolation precautions in hospitals. Part II. Recommendations for isolation precautions in hospitals. AJIC 24:32-52, 1996

• 2) Garner, J. S.:CDC Guidelines for the Prevention and Control of Nosocomial Infections. Guidelines for prevention of surgical wound infections, 1985. Am. J. Infect. Control 14 (2):71-82, 1986

• 3) Garner, J. S., Favero, M. S.:CDC Guidelines for the prevention and control of nosocomial infections. Guideline for handwashing and hospital environmental control, 1985. Supersedes guideline for hospital environmental control published in 1981. Am. J. Infect. Control 14 (3):110-129, 1986

• 4) Bolyard, E. A., Tablan, O. C., Williams, W. W. et al.:Guideline for infection control in health care personnel. AJIC 26 (3):289-354, 1998 and Infect. Control Hosp. Epidemiol. 19:407-463, 1998

• 5) CDC:Recommendations for Preventing Transmission of Human Immunodeficieney Virus and Hepatitis B Virus to Patients during Exposure-Prone lnvasive Procedures. MMU (R 40 (RR-8):1-9, 1991

• 6) Garner, J. S., Favero, M. S.:CDC Guidelines for the prevention and control of nosocomial infections. Guideline for handwashing and hospital environmental control, 1985. Supersedes guideline for hospital environmental control published in 1981. Am. J. Infect. Control 14 (3):110-129, 1986

• 7) CDC:Cryptosporidium and Water:A Public Health Handbook. Working Group on Waterborne Cryptosporidiosis, Atlanta, Georgia

• 8) Moe, G. L.:Low-microbial diets for patients with granulocytopenia. Chapter 12. (Bloch, A. S. ed.) Aspen Publishing, Inc., Rockville, MD, 1990, pp. 125-134

• 9) Aker, S. N.:Bone marrow transplantation:nutrition support and monitoring. Chapter 19. (Bloch, A. S. ed.) Aspen Publishing Inc., Rockville, MD, 1990, pp. 199-225

• 10) Aker, S. D.:Food Safety Guidelines During and After Transplantation. Fred Hutchinson Cancer Research Center Clinical Nutrition Department and Swedish Medical Center Nutrition Services Department. Seattle, WA, 1996

• 11) Remington, J. S., Schimpff, S. C.:Please don't eat the salads. N. Engl. J. Med. 304 (7):433-435, 1981

• 12) Philpott-Howard, J.:Prevention of fungal infections in hematology patients. Infect. Control Hosp. Epidemiol. 17:545-551, 1996

• 13) Schwab, A. H., Harpestad, A. D., Swartzentruber, A. et al.:Microbiological quality of some spices and herbs in retail markets. Appl. Environ. Microbiol. 44 (3):627-630, 1982
  pubmed

• 14) De-Bock, R., Gyssens, L, Peetermans, M., Nolard, N.:Aspergillus in pepper. Lancet ii:331-332, 1989

• 15) Hilton, E., Isenberger, H. D., Alperstein, P. et al.:Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Ann. Intern. Med. 116 (5):353-357, 1992

• 16) CDC:USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR 46 (RR-12):7-9, 40-41, 1997

• 17) CDC:Cryptosporidiosis. CDC/NCID.

• 18) 矢野邦夫:感染予防の話. 静岡新聞出版部, 静岡, 1999, pp. 164-173

P.316 掲載の参考文献

• 1) 日本環境感染学会 (編):病院感染防止指針. 南山堂, 1995, pp. 4

• 2) 向野賢治 (訳), 小林寛伊 (監訳):病院における隔離予防策のためのCDC最新ガイドライン<インフェクションコントロール別冊>. メディカ出版, 1996

• 3) 矢野久子:新しい感染制御看護の知識と実際<臨床看護セレクション2>. (小林寛伊監修) へるす出版, 1995, pp. 152-155

• 4) 矢野邦夫, 浦野美恵子:院内感染対策ガイド-米国疾病管理センター(CDC) による科学的対策. 日本医学館, 1998, pp. 38-41

• 5) Schaffer, S. D. et al. (編著), 藤村龍子 (監訳):感染管理看護の考え方と実際. 医学書院MYW, 1997

• 6) 日本感染症学会 (編):院内感染対策テキスト. へるす出版, 1999

• 7) 向野賢治:病院内隔離予防のあり方. 臨床医23 (10):38-40, 1997

• 8) 向野賢治:病院感染の動向と隔離の概念の変遷. INFECTION CONTROL 7 (3):30-33, 1998

P.326 掲載の参考文献

• 1) 佐々木次雄:ISO規格に準拠したバイオバーデン試験法及び環境微生物試験法. 日本規格協会, 東京, 1996, pp. 39-40

• 2) 小林寛伊, 大久保憲, 尾家重治:消毒と滅菌のガイドライン. へるす出版, 東京, 1999, pp. 9-100

• 3) Spaulding, E. H.:Chemical disinfection of medical and surgical materials. Disinfection, sterilization and preservation. (Lawrence, C. A., Block, S. S. eds.) Lea & Febiger, Philadelphia, 1968, pp. 517-531

• 4) Rutala, W. A.:APIC guideline for selection and use of disinfectants. Am. J. Infect. Control 24:313-342, 1996
  pubmed

• 5) Larson, E. L.:Alcohol for surgical scrubbing. Infect. Control Hosp. Epidemiol. 11:139-143, 1990
  pubmed

• 6) Larson, E. L.:Handwashing and skin. Physiologic and bacteriologic aspects. Infect. Control 6:14-23, 1985

• 7) Larson, E. L.:APIC guideline for handwashing and hand antisepsis in health care settings. Am. J. Infect. Control 23:251-269, 1995
  pubmed

• 8) O'Shaughnessy, M., O'Malley, V. P., Corvett, G., Given, H. F.:Optimum duration of surgical scrub time. Br. J. Surg. 78:685-686, 1991

• 9) AORN:Standards, recommended practices, guideline. Association of Operating Room Nurses, Inc., Denver, 1997

• 10) 小林寛伊:酸化エチレンガス滅菌. 手術部医学マニュアル(3). 文光堂, 東京, 1989, pp. 65-70

• 11) OSHA:Occupational exposure to ethylene oxide. Federal Resister 46:25734-25809, 1984

• 12) 細渕和成:プラズマ滅菌. 感染制御学. (小林寛伊編) へるす出版, 東京, 1996, pp. 108-113

P.337 掲載の参考文献

• 1) 岩田哲郎:病棟, 外来を含めての病院清掃. 感染と消毒4 (1):10-16, 1997

• 2) 佐藤懇一:病院の環境管理院内感染防止のためのメディカルクレンリネス&サニテーション30:9-10, 1995

P.347 掲載の参考文献

• 1) World Health Organization-Regional Office for Europe:Management of waste from hospitals and other health care establishments, EURO Reports and Studies 97. 1985

• 2) 厚生省水道環境部産業廃棄物対策課:廃棄物処理法に基づく感染性廃棄物処理マニュアル. 厚生省, 東京, 1992

• 3) 高月紘, 酒井伸一:有害廃棄物. 中央法規出版, 東京, 1993, pp. 101-111

P.356 掲載の参考文献

• 1) Yano, K. et al.:Surveillance of blood exposure to health care workers at Hamamatsu Medical Center. 第10回日本エイズ学会総会. 1996, 12, 6-7

• 2) 浦野美恵子, 矢野邦夫ほか:県西部浜松医療センタ-医療従事者における針刺し・切創事故に関するサーベイランスとコスト試算. 環境感染学会誌12:94-98, 1997

• 3) Shapiro, C. N.:Occupational risk of infection with hepatitis B and hepatitis C virus. Surg. Clin. North Am. 75:1047-1056, 1995
  pubmed

• 4) CDC:Advisory Committee on Immunization Practices and the Hospital Infection Control Practices Advisory Commitee. Immunization of Health Care Workers. MMWR (in press), 1997

• 5) Wainwright, R. B., Bulkow, L. R., Parkinson, A. J. et al.:Protection provided by hepatitis B vaccine in a Yupik Eskimo population-results of a 10-year study. J. Infect. Dis. 175:674-677, 1997

• 6) Hadler, S. C., Margolis, H. S.:Hepatitis B immunization:Vaccine types, efficacy, and indications for immunization. Current Topics in Infectious Diseases. (Remington, J. S., Swartz, M. N. ed.) Blackwell Scientific Publications, Boston, 1992, pp. 282

• 7) CDC:Guideline for infection control in health care personnel, 1998
  pubmed

• 8) CDC:Protection against viral hepatitis:recommendations of the Advisory Committee on Immunization Practices (ACIP) . MMWR 39 (RR-2):1-27, 1990

• 9) CDC:Hepatitis B virus:a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 40 (RR-13):1-25, 1991

• 10) Alter, M. J.:The detection, transmission, and outcome of hepatitis C virus infection. lnfect. Agents Dis. 2:155-166, 1993
  pubmed

• 11) Polish, L. B., Tong, M. J., Co, R. L. et al.:Risk factors for hepatitis C virus infection among health care personnel in a community hospital. Am. J. Infect. Control 21:196-200, 1993

• 12) Cooper, B. W., Krusell, A., Tilton, R. C. et al.:Seroprevalence of antibodies to hepatitis C virus in high-risk hospital personnel. Infect. Control Hosp. Epidemiol. 13:82-85, 1992
  pubmed

• 13) Zuckerman, J., Clewley, G., Griffiths, P. et al.:Prevalence of hepatitis C antibodies in clinical health-care workers. Lancet 343:1618-1620, 1994
  pubmed

• 14) Mitsui, T., Iwano, K., Masuko, K et al.:Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology 16:1109-1114, 1992
  pubmed

• 15) CDC:Public Health Service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C. MMWR 40 (RR-4):13-14, 1991

• 16) Alter, M. J.:The detection, transmission, and outcome of hepatitis C virus infection. Infect. Agents Dis. 2:155-166, 1993
  pubmed

• 17) CDC:Risk of acquiring hepatitis C for health-care workers and recommendations for prophylaxis and follow-up after occupational exposure. Hepatitis Surveillance Report 56:3-7, 1996

• 18) CDC:Recommendations for follow-up of health-care workers after occupational exposure to hepatitis C virus. MMWR 46:603-606, 1997
  pubmed

• 19) CDC:Case-control study of HIV serovonversion in health-care workers after percutaneous exposure to HIV-infected blood-France, United Kingdom, and United States, January 1988-August 1994. MMWR 44:929-933, 1995
  pubmed

• 20) CDC:Public Health Service Guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. MMWR 47 (RR-7), 1998

VI 各施設での感染対策

P.370 掲載の参考文献

• 1) Wenzel, R. P. ed.:Prevention and Control of Nosocomial Infections, 2nd ed. Williams & Wilkins, Baltimore, 1993

• 2) Ayliffe, G. A. J., Lowbury, E. J. L., Geddes, A. M., Williams, J. D. eds.:Control of Hospital Infection, 3rd ed. Chapman & Hall Medical, London, 1992

• 3) Cookson, B. D., Emmerson, M., Sedgwick, J. et al.:Standards in Infection Control in Hospitals Prepared by The Infection Control Standards Working Party. Public Health Laboratory Service, London, 1993

• 4) Garner, J. S.:The Hospital Infection Control Practices Advisery Committee:Guideline for Isolation Precautions in Hospitals. Infect. Control Hosp. Epidemiol. 17:54-80, 1996

• 5) 賀来満夫:感染制御の重要性と今後の課題聖マリアンナ医科大学雑誌25:249-259, 1997

• 6) 賀来満夫:院内感染の原因微生物. 院内感染予防対策ハンドブック. (厚生省保健医療局国立病院部政策医療課監, 国立大阪病院感染対策委員会編) 南江堂, 東京, 1998, pp. 9-15

• 7) 向野賢治 (訳), 小林寛伊 (監訳):病院における隔離予防策のためのCDC最新ガイドライン. INFECTION CONTROL別冊. メディカ出版, 1996

• 8) 賀来満夫ほか:総合病院における環境管理と検査. 日本臨床微生物学雑誌6:59-62, 1996

P.376 掲載の参考文献

• 1) Mangram, A. J., Horan, T. C., Pearson, M. L. et al.:Guideline for prevention of surgical site infection. Infect. Control Hosp. Epidemiol. 20:247-278, 1999

• 2) 小林寛伊, 大久保憲:手術部位感染防止ガイドライン, 1999 II. 手術部位感染防止に関する勧告. 手術医学20:209-213, 1999

• 3) 小林寛伊, 大久保憲:手術部位感染防止ガイドライン, 1999 I. 手術部位感染概要手術医学20:297-326, 1999

• 4) 粕田晴久:手術時手洗いの新しい考え方. OPE nursing 14:430-435, 1999

• 5) 田宮洋一:手術医における短時間の手術時手洗い-爪部のみブラッシングを行う2剤使用による方法. 手術医学18:394-399, 1997

• 6) Cruse, P., Foord, R.:The epidemiology of wound infection:a 10 year prospective study of 62,939 wounds. Surg. Clin. North Am. 60:27-40, 1980
  pubmed

• 7) Dodds, R. D., Guy, P. J., Peacock. A. M. et al.:Surgical glove perforation. Br. J. Surg. 75:966-968, 1988
  pubmed

• 8) Centers for Disease Control:Postsurgical infections associated with nonsterile implantable devices. MMWR. Morb. Mortal. Wkly. Rep. 41:263, 1992
  pubmed

• 9) Lidwell, O. M., Elson, R. A., Lowbury, E. J. et al.:Ultra clean air and antibiotics for prevention of postoperative infection. A multicenter study of 8052 joint replacement operations. Acta Orthop. Scand. 58:4-13, 1987

• 10) Favero, M. S., Manian, F. A.:Is eliminating flash sterilization practical? Infect. Control Hosp. Epidemiol. 14:479-480, 1993
  pubmed

• 11) Association for the Advancement of Medical Instrumentation:Flash sterilization:steam sterilization of patient care items for immediate use (ANSI/AAMI ST37-1996) Arlington (VA):Association for the Advancement of Medical Instrumentation, 1996

• 12) Sanderson, P. J.:Antimicrobial prophylaxis in surgery:microbiological factors. J. Antimicrob. Chemother. 31 (Suppl B):1-9, 1993

• 13) Page, C. P., Bohnen, J. M., Flecher, J. R. et al.:Antimicrobial prophylaxis for surgical wounds. Guidelines for clinical care. Arch. Surg. 128:79-88, 1993

• 14) Scher, K. S.:Studies on the duration of antibiotic administration for surgical prophylaxis. Am. Surg. 63:59-62, 1997
  pubmed

• 15) McDonald, M., Grabsch, E., Marshall, C., Forbes, A.:Single-versus multiple-dose antimicrobial prophylaxis for major surgery:a systematic review. Aust. N. Z. J. Surg. 68:388-396, 1998
  pubmed

P.382 掲載の参考文献

• 1) CDC:Draft guidelines for the prevention of oppoortunistic infection (OIs) in bone marrow transplant (BMT) recipients, 1999

• 2) Hambraeus, A., Malmborg, A. S.:The influence of different footwear on floor contamination. Scand. J. Infect. Dis. 11:243-246, 1979
  pubmed

• 3) Humphreys, H., Marshall, R. J., Ricketts, V. E. et al.:Theater over-shoes do not reduce operating theater floor bacterial counts. J. Hosp. Infect. 17:117-123, 1991

• 4) Weightman, N. C., Banfield, K. R.:Protective over-shoes are unnecessary in a day surgery unit. J. Hosp. Infect. 28:1-3, 1994

• 5) Weems, J. J. Jr, Davis, B. J., Tablan, O. C. et al.:Construction activity:an independent risk factor for invasive aspergillosis and zygomycosis in patients with hematologic malignancy. Infect. Control 8 (2):71-75, 1987
  pubmed

• 6) Krasinski, K., Holzman, R. S., Hanna, B. et al.:Nosocomial fungal infection during hospital renovation. Infect. Control 6 (7):278-282, 1985
  pubmed

• 7) Barnes, R. A., Rogers, T. R.:Control of an outbreak of nosocomial aspergillosis by laminar air-flow isolation. J. Hosp. Infect. 14 (2):89-94, 1989
  pubmed

• 8) Sheretz, F. J., Belani, A., Kramer, B. S. et al.:Impact of air filtration on nosocomial aspergillus infections. Unique risk to bone marrow transplant recipients. Am. J. Med. 83:709-718, 1987

• 9) Walsh, T. J., Dixon, D. M.:Nosocomial aspergillosis:environmental microbiology, hospital epidemiology, diagnosis and treatment. Eur. J. Epidemiol. 5 (2):131-142, 1989
  pubmed

• 10) CDC:Guidelines for prevention of nosocomial pneumonia. MMWR 46 (RR-1):1-79, 1997 or Respir. Care 39:1191-1236, 1994
  pubmed

• 11) Rhame, F. S., Streifel, A. J., Kersey, J. H. Jr, McGlave, P. B.:Extrinsic risk factors for pneumonia in the patient at high risk of infection. Am. J. Med. 76 (Suppl. 5A):42-52, 1984

• 12) Storb, R., Prentice, R. L, Buckner, C. D. et al.:Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. N. Engl. J. Med. 308:302-307, 1983
  pubmed

• 13) CDC:Guideline for handwashing and hospital environmental control.

• 14) CDC:Advisory Committee on Immunization Practices and the Hospital Infection Control Practices Advisory Commitee. Immunization of Health Care Workers. MMWR 1997

• 15) 矢野邦夫, 浦野美恵子:院内感染対策ガイド (CDCによる科学的な対策) . 日本医学館, 1998

• 16) 矢野邦夫:造血幹細胞移植のための感染対策ガイド. 日本医学館, 1999

P.393 掲載の参考文献

• 1) Ayliffe, G. A. J., Lowbury, E. J. L., Geddes, A. M. et al.:Control of Hospital Infection, Chapman & Hall Medical, London, 1992, pp. 295-299

• 2) 水口一衛, 高須昭彦, 佐々寛己:大垣市民病院集中治療室の現況. ICUとCCU 17:613-619, 1993

• 3) 大城誠, 高橋理栄子, 早川昌弘ほか:新生児集中治療室におけるメチシリン耐性黄色ブドウ球菌保菌児の減少-手袋着用の効果. 日本小児科学会雑誌102:1171-1175, 1998

• 4) 山本洋子:MRSAを含む院内感染総合対策の実践に関する研究. 平成8年度厚生科学研究報告書. 1997, pp. 36-39

• 5) Kollef, M. H.:The prevention of ventilator-associated pneumonia. N. Engl. J. Med. 340:627-634, 1999
  pubmed

• 6) Moro, M. L., Jepsen, O. B., EURO. NIS Study Group:Infection control practices in intensive care units of 14 European countries. Intensive Care Med. 22:872-879, 1996

• 7) Ingris, T. J. J., Sproat, L. J., Hawkey, P. M. et al.:Infection control in intensive care units; U. K. national survey. Br. J. Anaesth. 68:216-220, 1992

P.402 掲載の参考文献

• 1) Routledge, P. A.:Pharmacokinetics in children. J. Antimicrob. Chemother. 34 (Suppl. A):19-24, 1994

• 2) 佐藤吉壮:新生児感染症の抗菌薬療法. 小児感染免疫9 (1):43-48, 1997

• 3) Lewis, D. A., Reeves, D. S.:Antibiotics at the extremes of age:choices and constraints. J. Antimicrob. Chemother. 34 (Suppl. A):11-18, 1994

• 4) Weisman, L. E.:Advances in the treatment of neonatal sepsis and meningitis. Isr. J. Med. Sci. 30:455-458, 1994
  pubmed

• 5) Llorens, X. S., McCracken, G. H. Jr.:Perinatal bacterial disease. Textbook of pediatric infectious disease 4th edition. Saunders, Philadelphia, 1998, pp.892-926

• 6) Anker, J. N.:Ceftazidime pharmacokinetics in preterm infants:Effects of renal function and gestational age. Clin. Pharmacol. Ther. 58 (6):650-659, 1995
  pubmed

• 7) Anker, J. N.:The Effect of Asphyxia on the Pharmacokinetics of Ceftazidime in the Term Newborn. Pediatr. Res. 38 (5):808-811, 1995
  pubmed

P.410 掲載の参考文献

• 1) 稲松孝思:高齢者施設と感染対策. 院内感染対策テキスト. (日本感染症学会編) へるす出版, 東京, 1995, pp. 143-150

• 2) 山腰雅宏, 鈴木幹三, 山本俊信ほか:特別養護老人ホームで流行した高齢者インフルエンザA (H3N2) の検討. 感染症誌70:449-455, 1995

• 3) 鈴木幹三, 山腰雅宏:老人福祉施設における院内感染対策. 臨床医23:1972-1974, 1997

• 4) 山腰雅宏, 鳥居正芳:高齢者のインフルエンザ対策. INFECTION CONTROL 8:900-904, 1999

• 5) 廣田良夫, 加地正郎:インフルエンザワクチンの効果と副作用. 臨床と研究75:2558-2566, 1998

• 6) Center of Disease Control and Prevention:Prevention and control of influenza:part I, Vaccines-recommendations of the Advisory Committee on Immunization Practices (ACPI). MMWR 46 (RR-9):1-25, 1997

• 7) 加地正英, 加地正郎:高齢者へのインフルエンザワクチン接種-特に医療経済効果について. INFECTION CONTROL 7:1422-1426, 1998

• 8) Hirota, Y., Fedoson, D. S., Kaji, M.:Japan lagging in influenza jabs. Nature 380:18, 1996

• 9) 山腰雅宏, 鈴木幹三:インフルエンザ高齢者施設での対策. からだの科学210:54-57, 2000

• 10) 菅谷憲夫:新しいインフルエンザ薬-ノイラミニダーゼ阻害薬. 感染と抗菌薬2:289-293, 1999

• 11) 厚生省保健医療局結核感染症課:結核の統計1998. 財団法人結核予防会, 1998

• 12) 厚生省:結核緊急事態宣言. Mebio 16:80-81, 1999

• 13) 松浦徹:高齢者結核の病院感染と対策. INFECTION CONTROL 8:929-931, 1999

• 14) 高屋通子:高齢者の施設で流行する疹癬対策. INFECTION CONTROL 8:910-913, 1999

• 15) 荒田次郎:病癬. 治療創刊80巻記念増刊号:866-867, 1998

• 16) 厚生省老人保健福祉局老人福祉計画課 (監修):特別養護老人ホーム等における感染症対策の手引. 全国社会福祉協議会, 1994

P.420 掲載の参考文献

• 1) 城谷典保:在宅医療の動向と展望. 日医雑誌120 (9):1193-1196, 1998

• 2) 大林完二, 上田慶二, 山崎摩耶ほか:在宅医療のあり方. 日医雑誌120 (9):1177-1192, 1998

• 3) 鈴木幹三:高齢者の感染症. INFECTION CONTROL 7 (10):1310-1314, 1998

• 4) 川村佐和子, 南谷幹夫, 田村ひろみ:在宅感染管理のこれからの課題. 訪問看護と介護3 (3):203-212, 1998

• 5) 林泰吏, 鎌田ケイ子:在宅ケアでの褥瘡予防. 日医雑誌118 (2):203-206, 1997

• 6) 鈴木幹三:褥瘡. 往診・在宅・外来における感染症診断・治療ガイド. (永武毅) 医薬ジャーナル社, 東京, 1999, pp. 90-98

• 7) 村木良一:褥瘡の管理. 「医師」にとっての訪問看護. (茨城県医師会) 日本讐事新報社, 東京, 1997, pp. 137-145

• 8) 西村泰司, 阿部裕行:感染症の予防と管理 尿路感染症. 訪問看護と介護3 (3):182-188, 1998

• 9) 公文裕巳:病院と在宅をつなぐ感染対策 カテーテル管理を必要とする患者の退院指導. INFECTION CONTROL 7 (12):1542-1545, 1998

• 10) 中田まゆみ:II医療処置にかかわる指導・援助 1. 膀胱カテーテルの留置または交換. 老人訪問看護研修テキスト. (老人訪問看護研修事業等検討会) 日本看護協会出版会, 東京, 1992, pp. 144-147

• 11) 広瀬崇興:尿路カテーテル感染防止. 病院感染防止指針. (日本環境感染学会) 南山堂, 東京, 1995, pp. 114-121

• 12) 蝶名林直彦, 青島正夫, 押川真喜子ほか:病院と在宅をつなぐ感染対策 呼吸器疾患をもつ患者の退院指導. INFECTION CONTROL 7 (12):1524-1529, 1998

• 13) 山本俊信, 鳥居正芳, 鈴木幹三:高齢者肺炎-特に誤嚥性肺炎を中心に5. 予防. 化学療法の領域15 (6):858-862, 1999

• 14) 鈴木幹三:肺炎球菌ワクチン. 臨床と微生物25 (4):459-462, 1998

• 15) 中田まゆみ:II医療処置にかかわる指導・援助 4. 喀痰および気道内吸引. 老人訪問看護研修テキスト. (老人訪問看護研修事業等検討会) 日本看護協会出版会, 東京, 1992, pp. 154-157

• 16) 押川真喜子:聖路加国際病院訪問看護科における在宅での感染管理. 訪問看護と介護3 (3):197-202, 1998

• 17) 三浦明夫, 余田茂樹:在宅医療にふさわしい「物」と「技術」 在宅医療に取り組む企業の視点(2) 在宅栄養管理を可能にする方法・器材. 訪問看護と介護4 (7):509-518, 1999

• 18) 吉田洋, 山東勤弥, 和佐勝史ほか:在宅栄養管理-経腸, 経静脈栄養のマネジメント. 日医雑誌120 (9):1205-1208, 1998

VII 感染対策の組織化

P.441 掲載の参考文献

• 1) 大久保憲:感染対策ICT実践マニュアル. (賀来満夫編) メディカ出版, 大阪, 1997, pp. 8-16

• 2) 賀来満夫:院内感染対策のシステム化. 院内感染対策. (厚生省健康政策局指導課監, 日本感染症学会編) へるす出版, 東京, 1997, pp. 126-136

• 3) 三宅寿美:院内感染防止における英国の感染対策専門看護婦 (ICN) の役割. 医器学62:38-42, 1992

• 4) 三宅寿美:ICN (Infection Control Nurse) の必要性-イギリスで研修を受けて. EXPERT NURSE 7 (10):36-39, 1991

• 5) 三宅寿美:感染管理におけるICNの役割とその必要性-英国の状況を通して. 看護管理1 (4):220-229, 1991

• 6) 柴田清:インフェクション・コントロール・ナ-スの役割と業務の実際. EXPERT NURSE 13 (5):42-45, 1997

• 7) 広瀬千也子:米国ICPの活動と展望. 看護管理3 (6):360-365, 1993

• 8) 大久保憲:英国における病院感染制御教育プログラム. INFECTION CONTROL 8 (1):36-39, 1999

• 9) 柴田清:米国におけるICN教育プログラム. INFECTION CONTROL 8 (1):20-21, 1999

• 10) 鍋谷桂子, 市場ゆかり, 金沢きみ代ほか:外国の病院に学ぶ院内感染対策-イギリスにおけるLink Nurseの役割. 環境感染13 (4):272-275, 1998

• 11) 廣瀬千也子:日本看護協会による感染看護の短期教育講座. INFECTION CONTROL 8 (1):14-18, 1999

P.451 掲載の参考文献

• 1) 中野一司, 丸山征郎:Evidence-based medicine (EBM) を可能にする臨床検査システムの必須条件. 日本臨床57増刊号:11-17, 1999

• 2) 中野一司, 松下昌風, 永田四郎ほか:鹿児島大学病院総合臨床検査システム. 新医療別冊95臨床検査機器システムガイド:54-59, 1995

• 3) 中野一司, 丸山征郎:鹿児島大学医学部附属病院検査部での取り組み-より付加価値の高い検査部の構築に向けて. 臨床病理46:1089-1096, 1998